Protalix Biotherapeutics Inc. is a biopharmaceutical company focused on developing and manufacturing therapeutic proteins using its proprietary plant cell-based expression system. This innovative platform allows for the production of recombinant proteins, offering advantages such as scalability and cost-effectiveness compared to traditional mammalian cell culture methods. Protalix is prominently engaged in advancing solutions within the rare diseases sector, exemplifying its commitment to addressing unmet medical needs. One of its leading products targets Gaucher disease, a hereditary enzyme deficiency disorder. Serving global pharmaceutical markets, Protalix collaborates with international partners to commercialize and distribute its therapies. The company’s research and development efforts emphasize expanding the therapeutic potential of its platform, thereby contributing significantly to the biotechnology industry. Based in the biotechnology hub of Israel, Protalix Biotherapeutics Inc. plays an important role in the biopharmaceutical field, pushing the horizons of innovative treatment options and impacting the healthcare sector by striving to improve patient outcomes for rare, genetic conditions.